Dermira Inc (NASDAQ:DERM) insider Eugene A. Bauer sold 3,000 shares of Dermira stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $27.34, for a total transaction of $82,020.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Dermira Inc (NASDAQ DERM) traded up $1.20 on Wednesday, reaching $27.87. 424,704 shares of the company’s stock traded hands, compared to its average volume of 428,871. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira Inc has a 12 month low of $21.35 and a 12 month high of $38.75.

DERM has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated a “buy” rating and issued a $45.00 target price on shares of Dermira in a report on Monday, November 6th. Zacks Investment Research downgraded shares of Dermira from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Guggenheim initiated coverage on shares of Dermira in a report on Tuesday, December 5th. They issued a “buy” rating for the company. Leerink Swann restated an “outperform” rating and issued a $41.00 target price (down from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Finally, Mizuho restated a “buy” rating and issued a $43.00 target price (up from $40.00) on shares of Dermira in a report on Thursday, September 7th. Four research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Dermira currently has a consensus rating of “Hold” and a consensus target price of $41.00.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its position in shares of Dermira by 15.6% during the second quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock worth $114,294,000 after purchasing an additional 529,405 shares in the last quarter. Jennison Associates LLC raised its holdings in Dermira by 0.3% in the third quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock valued at $71,300,000 after acquiring an additional 7,746 shares in the last quarter. Vanguard Group Inc. raised its holdings in Dermira by 9.8% in the second quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock valued at $40,735,000 after acquiring an additional 125,157 shares in the last quarter. Voya Investment Management LLC raised its holdings in Dermira by 61.4% in the second quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock valued at $35,783,000 after acquiring an additional 467,356 shares in the last quarter. Finally, State Street Corp raised its holdings in Dermira by 38.4% in the second quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock valued at $23,946,000 after acquiring an additional 228,093 shares in the last quarter. Institutional investors own 99.47% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Dermira Inc (DERM) Insider Eugene A. Bauer Sells 3,000 Shares” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/12/20/dermira-inc-derm-insider-eugene-a-bauer-sells-3000-shares.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.